## Background: Receptors for luteinizing hormone-releasing hormone (lh-rh) found in prostate cancers might be used for targeting of chemotherapeutic agents. doxorubicin derivative 2-pyrrolinodoxorubicin (an-201) can be linked to carrier analog [d-lys6]lh-rh to form the targeted cytotoxic analog of
Topography and associations of luteinizing hormone–releasing hormone and neuropeptide Y–immunoreactive neuronal systems in the human diencephalon
✍ Scribed by Bertalan Dudás; András Mihály; István Merchenthaler
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 692 KB
- Volume
- 427
- Category
- Article
- ISSN
- 0021-9967
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Experiments have been performed to clarify whether LHRH agonists might decrease growth of hormone-unresponsive prostate cancer in vivo. Male nude mice were injected s.c. with the human androgen-independent prostate tumor DU 145 cells; osmotic minipumps releasing the LHRH agonist Zoladex (LHRH-A) for
## Background: Metastatic or recurrent renal cell carcinoma (rcc) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. no uniformly effective therapeutic agents are available for the management of patients with rcc. hormones and growth factors may play a rol
This study is the first to examine the brain gonadotropin-releasing hormone (GnRH) cell population phenotype in a protogynous and monandric sequentially hermaphroditic fish. Male ballan wrasse (Labrus berggylta) had on average higher numbers of GnRH-immunoreactive (GnRH-ir) cells within the brain pr